Pediatric patients with CML exhibited initially elevated osteocalcin levels followed by a significant decline of 0.3 μg/L per week on imatinib treatment [42]. This evidence concerns the gene BGLAP and chronic myelogenous leukemia, BCR-ABL1 positive.